SCHEMBL5320201

SCHEMBL5320201

CC/C(=C(\c1ccc(C)cc1)c1ccc(OCCN(C)C)cc1)c1ccccc1

nearest known ligand 0.90

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 8/20 0.90
ESR2 Q92731 6/20 0.90
MAPT P10636 3/20 0.90
ESRRG P62508 3/20 0.90
MEN1 O00255 3/20 0.90
TP53 P04637 3/20 0.90
CYP3A4 P08684 3/20 0.90
KMT2A Q03164 3/20 0.90
PGR P06401 2/20 0.90
CYP1A2 P05177 2/20 0.90
CYP2D6 P10635 2/20 0.90
HTR6 P50406 2/20 0.90
NPC1 O15118 1/20 0.90
NR1I2 O75469 1/20 0.90
PRKD3 O94806 1/20 0.90
ABCB11 O95342 1/20 0.90
EGFR P00533 1/20 0.90
GBA1 P04062 1/20 0.90
NR3C1 P04150 1/20 0.90
ERBB2 P04626 1/20 0.90

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16575061 1.00 ESR1 (0.90) ESR1ESR2MAPTESRRGMEN1
SCHEMBL2615530 1.00 ESR1 (0.90) ESR1ESR2MAPTESRRGMEN1
Tamoxifen SCHEMBL4084 0.95 ESR1 (1.00) ESR1ESR2MAPTESRRGMEN1
Tamoxifen SCHEMBL17262111 0.95 ESR1 (1.00) ESR1ESR2MAPTESRRGMEN1
Tamoxifen SCHEMBL119181 0.95 ESR1 (1.00) ESR1ESR2MAPTESRRGMEN1
SCHEMBL29659348 0.95 ESR1 (1.00) ESR1ESR2MAPTESRRGMEN1
Tamoxifen SCHEMBL4085 0.95 ESR1 (1.00) ESR1ESR2MAPTESRRGMEN1
Tamoxifen SCHEMBL17262082 0.95 ESR1 (1.00) ESR1ESR2MAPTESRRGMEN1
Tamoxifen SCHEMBL1056785 0.95 ESR1 (1.00) ESR1ESR2MAPTESRRGMEN1
Tamoxifen SCHEMBL5789295 0.93 ESR1 (0.97) ESR1ESR2MAPTESRRGMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3927434-B1 ACYL-COA SYNTHETASE 4 (ACSL4) INHIBITORY COMPOUND CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECN CONICET (AR) 2024-10-16 EP claimed
WO-2007098090-A2 TREATMENT OF HYPERPROLIFERATIVE DISEASES WITH N-OXIDES OF ESTROGEN RECEPTOR MODULATORS NOVACEA, INC. (US) 2007-08-30 WO claimed
US-20250255959-A1 A SYSTEM FOR DRUG-INDUCIBLE EXPRESSION OF A POLYNUCLEOTIDE Miltenyi Biotec B.V. & Co. KG (DE) 2025-08-14 US disclosed
US-20250074959-A1 ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A TRANSCRIPTION FACTOR AND A HEAT SHOCK PROTEIN 90 BINDING DOMAIN SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) 2025-03-06 US disclosed
EP-4504243-A1 A SYSTEM FOR DRUG-INDUCIBLE EXPRESSION OF A POLYNUCLEOTIDE Miltenyi Biotec B.V. & Co. KG (DE) 2025-02-12 EP disclosed
US-12202897-B2 Drug regulated transgene expression SEATTLE CHILDREN'S HOSPITAL (US) 2025-01-21 US disclosed
CN-118973608-A System for drug-induced expression of polynucleotides 美天施生物科技有限两合公司 2024-11-15 CN disclosed
US-20240226160-A9 ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) 2024-07-11 US disclosed
US-20240131072-A1 ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) 2024-04-25 US disclosed
EP-4341283-A2 ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A TRANSCRIPTION FACTOR AND A HEAT SHOCK PROTEIN 90 BINDING DOMAIN Seattle Children's Hospital d/b/a Seattle Children's Research Institute (US) 2024-03-27 EP disclosed
EP-4291571-A2 ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN Seattle Children's Hospital d/b/a Seattle Children's Research Institute (US) 2023-12-20 EP disclosed
EP-2822955-B1 BORON-BASED 4-HYDROXYTAMOXIFEN AND ENDOXIFEN PRODRUGS AS TREATMENT FOR BREAST CANCER XAVIER UNIV (US) 2017-07-26 EP disclosed
WO-2017123548-A1 TUMOR-SPECIFIC IFNA SECRETION BY CAR T-CELLS TO REPROGRAM THE SOLID TUMOR MICROENVIRONMENT Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) 2017-07-20 WO disclosed
US-20170152297-A1 DRUG REGULATED TRANSGENE EXPRESSION Seattle Children's Hospital (dba Seattle Children's Research Institute) 2017-06-01 US disclosed
WO-2017027291-A1 BISPECIFIC CAR T-CELLS FOR SOLID TUMOR TARGETING Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) 2017-02-16 WO disclosed
EP-3129399-A1 DRUG RELATED TRANSGENE EXPRESSION Seattle Children's Hospital, dba Seattle Children's Research Institute (US) 2017-02-15 EP disclosed
WO-2015157432-A1 DRUG RELATED TRANSGENE EXPRESSION Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) 2015-10-15 WO disclosed
US-9056141-B2 Thiol-ene click chemistry for drug conjugates SYNCHEM, INC. (US) 2015-06-16 US disclosed
EP-1196163-B1 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF INSULIN RESISTANCE ENDORECH INC (CA) 2009-11-11 EP disclosed
WO-2007098090-A2 TREATMENT OF HYPERPROLIFERATIVE DISEASES WITH N-OXIDES OF ESTROGEN RECEPTOR MODULATORS NOVACEA, INC. (US) 2007-08-30 WO disclosed